RMC 035

Drug Profile

RMC 035

Alternative Names: A1M-001; Alpha-1-microglobulin - A1M Pharma; RMC-035; ROSGard; α1-microglobulin - A1M Pharma

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator A1M Pharma AB
  • Class Recombinant proteins
  • Mechanism of Action Antioxidants; Free radical scavengers; Haemoglobin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Preeclampsia
  • Preclinical Acute kidney injury

Most Recent Events

  • 12 Jun 2017 A1M Pharma plans a safety clinical trial of RMC 035 (In volunteers)
  • 29 Mar 2017 Preclinical trials in Acute kidney injury (Prevention) in Sweden (Parenteral)
  • 29 Mar 2017 Pharmacodynamics data from preclinical studies in Acute kidney injury (Prevention) released by A1M Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top